Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Isaralgagene civaparvovec (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Sangamo Therapeutics
- 14 Sep 2021 New trial record